Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 1/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 2/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.69 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.69 |
| ▸ | MITF | O75030 | 1/20 | 0.64 |
| ▸ | PPARG | P37231 | 1/20 | 0.64 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.60 |
| ▸ | TCF4 | P15884 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 3/20 | 0.59 |
| ▸ | RAB9A | P51151 | 2/20 | 0.59 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20534442 | 1.00 | CA9 (0.74) | CA9MAPK1MAPTALDH1A1NCOA3 | |
| SCHEMBL20534423 | 0.93 | MAPT (0.79) | CA9MAPK1MAPTALDH1A1NCOA3 | |
| SCHEMBL20534421 | 0.93 | MAPT (0.79) | CA9MAPK1MAPTALDH1A1NCOA3 | |
| SCHEMBL12008788 | 0.89 | MAPT (0.87) | MAPK1MAPTALDH1A1NCOA3MITF | |
| SCHEMBL21783159 | 0.88 | PPARG (0.76) | CA9MAPK1MAPTALDH1A1NCOA3 | |
| SCHEMBL8188771 | 0.85 | CA9 (1.00) | CA9PPARG | |
| SCHEMBL8188774 | 0.85 | CA9 (1.00) | CA9PPARG | |
| SCHEMBL13446896 | 0.85 | MMP1 (0.73) | CA9MAPTALDH1A1MITFNPC1 | |
| SCHEMBL31376923 | 0.85 | MYC (0.68) | CA9MAPTALDH1A1MITFCTNNB1 | |
| SCHEMBL21783150 | 0.83 | PPARG (0.79) | CA9MAPK1MAPTALDH1A1NCOA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200068890-A1 | HETEROCYCLIC INHIBITORS OF LYSINE BIOSYNTHESIS VIA THE DIAMINOPIMELATE PATHWAY | LA TROBE UNIVERSITY (AU) | 2020-03-05 | — | — | US | disclosed |
| EP-3609494-A1 | HETEROCYCLIC INHIBITORS OF LYSINE BIOSYNTHESIS VIA THE DIAMINOPIMELATE PATHWAY | La Trobe University (AU) | 2020-02-19 | — | — | EP | disclosed |
| CN-110621315-A | Heterocyclic inhibitors of lysine biosynthesis via the diaminopimelic acid pathway | 拉筹伯大学 | 2019-12-27 | — | — | CN | disclosed |
| WO-2018187845-A1 | HETEROCYCLIC INHIBITORS OF LYSINE BIOSYNTHESIS VIA THE DIAMINOPIMELATE PATHWAY | LA TROBE UNIVERSITY (AU) | 2018-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200068890-A1 | HETEROCYCLIC INHIBITORS OF LYSINE BIOSYNTHESIS VIA THE DIAMINOPIMELATE PATHWAY | DDC, ODC1, DDT | CA9 2233/4885MAPK1 463/4885MAPT 3729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.